AstraZeneca (AZN) has released an update.
AstraZeneca’s Imfinzi has shown a significant improvement in survival rates for patients with limited-stage small cell lung cancer in their ADRIATIC Phase III trial, marking a potential breakthrough in treatment. This is the first global Phase III trial where an immunotherapy has improved overall and progression-free survival in this context. The results, consistent with Imfinzi’s known safety profile, will be presented at an upcoming medical meeting and are set to be discussed with global regulatory authorities.
For further insights into AZN stock, check out TipRanks’ Stock Analysis page.
